Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07385664
Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC (FAIR)
A Phase II Study of Neoadjuvant Chemoimmunotherapy or Concurrent Chemoradiotherapy Guided by Post-Chemoimmunotherapy FAPI-PET/CT
Sponsor: Ji Yongling
Conditions
Resectable Esophageal Cancer
Updated 1 time since 2026 Last updated: Jan 26, 2026 Started: Jan 28, 2026 Primary completion: Jan 30, 2027 Completion: Feb 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Resectable Esophageal Cancer and is currently actively recruiting participants. Ji Yongling leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Ji Yongling
Data source: Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .